Antimicrobial-resistant ESKAPE (E nterococcus faecium, S taphylococcus aureus, K
lebsiella pneumoniae, A cinetobacter baumannii, P seudomonas aeruginosa, and E …

P. aeruginosa is classified as a priority one pathogen by the World Health Organisation, and
new drugs are urgently needed, due to the emergence of multidrug-resistant (MDR) strains …

Carbapenems are considered as last-resort antibiotics for the treatment of infections caused
by multidrug-resistant Gram-negative bacteria. With the increasing use of carbapenems in …

Relebactam (formerly known as MK-7655) is a non-β-lactam, bicyclic diazabicyclooctane, β-
lactamase inhibitor that is structurally related to avibactam, differing by the addition of a …

Abstract Multidrug-resistant (MDR) Gram-negative bacteria (GNB) pose a critical threat to
global healthcare, worsening outcomes and increasing mortality among infected patients …

Infections in the ICU are often caused by Gram-negative bacteria. When these
microorganisms are resistant to third-generation cephalosporines (due to extended …

Background Standard treatments against bacterial infections are becoming ineffective due to
the rise of antibacterial resistance worldwide. Classical approaches to develop new …

Imipenem/cilastatin/relebactam (Recarbrio™) is an intravenously administered combination
of the carbapenem imipenem, the renal dehydropeptidase-I inhibitor cilastatin, and the novel …

Microbial pathogens including Enterobacteriaceae family members bear different antibiotic
resistance genes comprising Extended-Spectrum-ß-Lactamases (ESBLs) and Metallo-ß …

Pseudomonas aeruginosa is a common pathogen that is associated with multidrug-resistant
(MDR) and carbapenem-resistant (CR) phenotypes; therefore, we investigated its resistance …